Click Here to Go Directly to the Story
Register/Subscribe
Home

 
 


U.S. EDITION
Full Table of Contents
 Cover Story
Special Report -- Executive MBAs
Special Report
Up Front
Editor's Memo
Readers Report
Corrections & Clarifications
Letter From New York City
Books
Technology & You

Economic Viewpoint
Economic Trends
Business Outlook
News: Analysis & Commentary
In Business This Week
Washington Outlook
Science & Technology
Developments to Watch
The Corporation
Entertainment

Finance
Sports Business
BusinessWeek Lifestyle
BusinessWeek Investor
The Barker Portfolio
Inside Wall Street
Figures of the Week
Editorials


INTERNATIONAL EDITIONS
International -- Readers Report
International -- Int'l Business
International -- Int'l Figures of the Week


OCTOBER 15, 2001

INSIDE WALL STREET

Checking Cholesterol

 
By Mara Der Hovanesian
Mara Der Hovanesian

  STORY TOOLS
Printer-Friendly Version
E-Mail This Story

Related Items Chart: Pulsing Upward
INSIDE WALL STREET

 Checking Cholesterol

Elcor's Factories Are Humming

Still Looking Chic at Chico's
Sometimes, a stock is such a secret that even Wall Street is kept in the dark. Take Cholestech (CTEC ), an up-and-comer in diagnostic testing that has no analyst coverage as yet. More than a defensive play, this may be a chance to get the jump on some promising growth. Cholestech has a device--smaller than a toaster--that measures "good" and "bad" cholesterol, using just a pinprick of blood rather than the usual vial. Results are available at the doctor's office in five minutes, while standard tests require a week's wait.

The shares have soared from 3.68 in March to a 52-week high of 18 on Oct. 3. The jump was powered by record revenues of $12.4 million--up 35% from a year ago--for the fiscal first quarter through June. Profits rose 13% in the same period. A National Institutes of Health announcement of cholesterol-testing guidelines in May also played to Cholestech's strengths.

In April, William Burke, a Bear Stearns investment banking veteran, became chief financial officer--and has talked up Cholestech to institutional investors. "If this is the beginning of institutional inflows and more coverage, it could be a big step," says Mathew Arens of Kopp Investment Advisors, which owns 1.6 million shares, or 13% of the company.

With a new production line, Arens sees 25%-a-year sales growth--which "will definitely translate to earnings"--and he expects the price to double in a year. Arens adds that Cholestech, a micro-cap company at $200 million, may be buyout bait for a medical-device outfit such as Boehringer-Ingelheim or a drugmaker like Pfizer, which already has a $7 million testing contract with Cholestech and a big roster of cholesterol-lowering drugs.


By Mara Der Hovanesian
Get BusinessWeek directly on your desktop with our RSS feeds.XML

Add BusinessWeek news to your Web site with our headline feed.

Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.

To subscribe online to BusinessWeek magazine, please click here.

Learn more, go to the BusinessWeekOnline home page
Back to Top

OCTOBER
 [an error occurred while processing this directive]


Copyright 2001, Bloomberg L.P.
Terms of Use | Privacy Policy

Media Kit | Special Sections | MarketPlace | Knowledge Centers
Bloomberg L.P.